Neutra Corp. income statement NTRR

Annual Quarterly

In Q3 of fiscal 2024, the quarter ended Oct 31, 2023, Neutra Corp. reported revenue of $1,311, down 94.4% from the same quarter a year earlier. It recorded a net loss of $54,986. The operating loss came to $52,728, an operating margin of -4022.0%.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Oct 31, 2023	Q3 FY2024 Oct 31, 2023	Q2 FY2024 Jul 31, 2023	Q1 FY2024 Apr 30, 2023	Q4 FY2023 Jan 31, 2023	Q3 FY2023 Oct 31, 2022	Q2 FY2023 Jul 31, 2022	Q1 FY2023 Apr 30, 2022	Q4 FY2022 Jan 31, 2022
Revenue	0 -82.7%	0 -94.4%	0 -85.1%	0 -39.5%	0 -84.6%	0 -11.0%	0 +83.7%	0 -16.4%	0 +1629.0%
Cost of revenue	0 -76.2%	0 -94.3%	0 -78.8%	0 -33.1%	0 -69.2%	0 -48.4%	0 -23.6%	0 -55.8%	0 -76.5%
Gross profit	0 -86.9%	0 -94.5%	0 -89.8%	0 -45.3%	0 -89.7%	0 +547.4%	0 +3259.0%	0 +296.6%	0 +174.1%
Selling, general and administrative	0 -43.5%	0 -6.4%	0 -11.1%	0 -32.7%	0 -73.6%	0 -69.5%	0 -33.7%	0 -26.6%	0 -21.3%
Operating income	-0 +36.7%	-0 +20.2%	-0 +12.8%	-0 +22.1%	-0 +64.0%	-0 +62.3%	-0 +34.2%	-0 +25.5%	-0 +35.5%
Interest expense	0 -70.8%	0 -85.6%	0 -99.8%	0 -98.7%	0 +2.8%	0 +4.1%	0 -4.5%	0 +7.7%	0 +793.2%
Pretax income	—	-0	-0	-0	—	—	—	—	—
Income tax	—	0	0	0	—	—	—	—	—
Net income	-0 -2.5%	-0 +32.8%	-0 +26.3%	-0 +32.8%	-0 -56.5%	-0 +54.3%	-0 +30.8%	-0 +21.9%	-0 +28.8%
Other measures
Depreciation and amortization	0 -22.0%	0 -54.1%	0 -33.9%	0 +0.0%	0 +0.0%	0 +0.0%	0 -2.0%	0 +8.3%	0 +48.3%
EBITDA	-0 +40.3%	-0 +5.8%	-0 +6.2%	-0 +28.2%	-0 +73.0%	-0 +70.2%	-0 +40.3%	-0 +31.3%	-0 +40.2%
Interest coverage	-14.07x	-23.35x	-2,474.79x	-357.83x	-3.72x	-4.20x	-5.46x	-5.81x	-10.64x
Margins
Gross margin	46.15%	44.93%	38.89%	48.00%	49.91%	45.65%	57.02%	53.03%	74.89%
Operating margin	-1,457.11%	-4,021.97%	-1,659.40%	-1,218.90%	-976.33%	-282.57%	-283.65%	-946.62%	-418.59%
Pretax margin	—	-4,194.20%	-1,660.07%	-1,222.30%	—	—	—	—	—
Profit margin	-2,723.64%	-4,194.20%	-1,661.20%	-1,232.39%	-4,646.11%	-349.79%	-335.58%	-1,109.46%	-457.94%
EBITDA margin	-1,103.36%	-3,331.58%	-1,357.92%	-881.24%	-643.05%	-198.21%	-215.70%	-742.45%	-367.20%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as: NTRR (OTC)
Fiscal year ends: January 31
Incorporated in: WY
Headquarters: Houston, TX
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1512886

Other Medicinal Chemicals & Botanical Products companies

All 43 Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.